[Ip-health] Gilead Remdesivir Licenses: Half measures are not nearly good enough

Baker, Brook b.baker at northeastern.edu
Wed May 13 07:47:49 PDT 2020

Joel is right that the relative effectiveness of remdesivir is still to be confirmed.  Moreover, remdesivir is currently only available as an infusion, which makes its applicability in LMICs much less promising for mass use.  However, getting started early on issuing compulsory licenses is not the same as committing to full-scale implementation of the CL and treatment of the population before adequate proof of safety/efficacy is established.

On 5/12/20, 10:15 PM, "Joel Lexchin" <joel.lexchin at utoronto.ca> wrote:

    Hi Brook:
    I have no argument with what you said about Gilead and the way its approaching access to remdesivir. However, I’m wondering about whether it might be better to wait for the peer reviewed publication of the remdesivir study before advocating that countries start to issue compulsory licenses. It might turn out to be less effective than the preliminary analysis indicated in which case countries could have used up valuable resources on something that is not that useful.
    Joel Lexchin MD
    Associate Professor
    Department of Family and Community Medicine
    University of Toronto
    E mail:	joel.lexchin at utoronto.ca	

More information about the Ip-health mailing list